Jefferies initiated coverage of BridgeBio (BBIO) with a Buy rating and $70 price target The firm believes Attruby could become a blockbuster pill with $4B in sales in transthyretin amyloid cardiomyopathy. Doctor channel checks checks suggesting upside if Attruby’s real-world efficacy proves differentiated over Pfizer’s (PFE) tafamidis, the analyst tells investors in a research note. Jefferies likes BridgeBio’s risk/reward at current share levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Pharma’s BBP-418: A Promising Investment in Groundbreaking LGMD2I/R9 Therapy
- BridgeBio price target raised to $67 from $58 at Citi
- Microsoft upgraded, Instacart initiated: Wall Street’s top analyst calls
- Oppenheimer upgrades BridgeBio on execution, data catalysts
- BridgeBio upgraded to Outperform from Perform at Oppenheimer